ASH 2018 Conference Review - focus on MM, reviewed by A/Prof Hang Quach

In this review:

Adding daratumumab to lenalidomide/dexamethasone for SCT-ineligible newly diagnosed MM
Deep and durable responses with selinexor + dexamethasone in pentarefractory MM
Maintenance ixazomib significantly prolongs PFS after autologous SCT in newly diagnosed MM
Anti-BCMA CAR T-cell therapy for relapsed/refractory MM
Anti-BCMA BITE antibody construct induces MRD-negative CRs in relapsed/refractory MM
Double vs. single autologous SCT for newly diagnosed MM
Persistent MRD in standard- vs. high-risk cytogenetic MM
Lenalidomide maintenance vs. continued lenalidomide/dexamethasone in intermediate-fit newly diagnosed MM
Venetoclax/carfilzomib/ dexamethasone in relapsed/refractory MM
Carfilzomib vs. bortezomib + cyclophosphamide/dexamethasone for relapsed/refractory MM

Please login below to download this issue (PDF)